1.Aulimodi raw materials and tablets received clinical approval from the NMPA on October 18, 2016.
2.Omarigliptin hydrochloride raw materials and tablets received clinical approval from the NMPA on January 16, 2017.
Address5/F, Jihao Building, 1086 Shennan East Road, Luohu District, Shenzhen
Adverse drug reactions / Event feedback hotline025-6816 1304
Adverse drug reactions / Event feedback mailGVP@changao.com
Official WeChat account 
Mobile page